Drug Database
OM

omeprazole (Omez Insta)

✓ Approved

Dr.Reddy's Laboratories Ltd. · ATP4A · Small Molecule

What is omeprazole?

omeprazole is a small molecule developed by Dr.Reddy's Laboratories Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOmez Insta
CompanyDr.Reddy's Laboratories Ltd.
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Dr.Reddy's Laboratories Ltd.

Mechanism of Action

Molecular Targets

omeprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

omeprazole is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Gastrointestinal disordersGastritis✓ Approved

Related Research Articles

PubMedClinical pharmacology and therapeutics2026-10-15

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19-Genotyped Patients.

Hole Kristine K, Wollmann Birgit M BM, Stingl Julia Carolin JC, Molden Espen E

Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real-life studies show a high degree of genotype-phenotype mismatch in escitalopram metabolism. The present study aimed to identify comedication with proton pump inhibitors (PPIs) and quantify phenoconversion of escitalopram metabolism in CYP2C19-genotyped patients by reprocessing high-resolution mass spectra from therapeutic drug monitoring (TDM) analyses. Patients were included from a combined TDM/pharmacogenetics (PGx) laboratory facility in Oslo, Norway. TDM profiles of escitalopram and CYP2C19 genotypes were available in the laboratory database. Reprocessing of high-resolution mass spectra by exact mass and fragment detection identified possible comedication with pantoprazole, esomeprazole/omeprazole or lansoprazole using mzCloud reference library. Patients were grouped as normal metabolizers (NMs), intermediate metabolizers (IMs), poor metabolizers (PMs), rapid metabolizers (RM), or ultrarapid metabolizers (UM). Primary outcome measure was N-desmethylescitalopram-to-escitalopram metabolic ratio (MR; CYP2C19 biomarker) in UMs vs. PMs. 2818 patients were included, constituting 2373 without and 445 (15.8%) with PPIs. Most patients were females (64.2%). Regarding CYP2C19 phenotype distribution, the cohort comprised 39.3% NMs, 29.3% IMs, 2.6% PMs, 24.6% RMs, and 4.2% UMs. Escitalopram MR was 4.5-fold higher in CYP2C19 UMs vs. PMs without PPIs (P < 0.001), while this difference was 2.8-fold in pantoprazole users (P < 0.001), and 1.8-fold in esomeprazole/omeprazole users (P = 0.2). In conclusion, PPIs show significant phenoconversion of CYP2C19-mediated escitalopram metabolism with esomeprazole/omeprazole exhibiting a stronger effect than pantoprazole. The novel method for identification of interacting comedications in TDM samples illustrates the innovative potential of high-resolution mass spectrometry in precision medicine.

PMID 42876187
Read full article →
PubMedHelicobacter2026-10-13

Efficacy of Standard Triple Therapy With or Without Statin in Helicobacter pylori Eradication: A Randomized Double-Blind Placebo-Controlled Trial.

Rattananukrom Chitchai C, Waranophirun Punnaphol P, Panitchote Anupol A, Vannaprasaht Suda S et al.

Standard triple therapy (STT) for Helicobacter pylori (H. pylori) infection has become suboptimal. Atorvastatin may improve eradication rates by promoting autophagy and reducing inflammation. This study aimed to evaluate the efficacy and safety of adjuvant atorvastatin with STT compared to STT alone for H. pylori eradication. In this randomized, placebo-controlled trial, 138 treatment-naïve patients with H. pylori infection were randomized to two groups. The intervention group (n = 70) received a 14-day regimen of omeprazole, amoxicillin, clarithromycin, and atorvastatin (40 mg once daily). The control group (n = 68) received the same regimen with a matching placebo. The primary endpoint was H. pylori eradication, assessed by a urea breath test 4-6 weeks after treatment completion. Secondary endpoints included CYP2C19 and CYP3A4/5 genotypes, adverse events, and patient compliance. The eradication rate in the intervention group was significantly higher than in the control group in both the per-protocol (97.1% vs. 85.3%) and intention-to-treat (ITT) analyses (95.7% vs. 85.3%). The absolute risk difference for the ITT analysis was 10.4% (95% CI, 0.75 to 20.1; p = 0.03). The distribution of CYP2C19 and CYP3A4/5 genotypes was similar between groups. No clinically significant differences in adverse events were observed. Adjuvant therapy with atorvastatin combined with STT significantly improved H. pylori eradication rates without clinically significant adverse events. Further randomized controlled trials in diverse populations and with varying antibiotic resistance patterns are needed to better clarify the effects of statins on H. pylori treatment. Thai Clinical Trial Registry, No. TCTR20220201001.

PMID 42866928
Read full article →
PubMedJournal of ethnopharmacology2026-10-13

Artemisia vulgaris and sabinene ameliorate gastric ulceration and its recurrence through modulation of acid secretion, oxidative stress, and inflammatory cytokines: an in vivo and in silico study.

Borba Ana Laura Tomaselli ALT, Freschi Khetlyn K, Miorando Daniela D, Maccagnan Juliana Cristina JC et al.

Artemisia vulgaris L., popularly known as mugwort, is traditionally used to treat gastric disturbances, yet the mechanistic basis of its antiulcer effects is largely unexplored. The study evaluated the gastroprotective, healing, and anti-recurrence effects of the hydroalcoholic extract of A. vulgaris (HEAv) and its constituent sabinene, and their underlying pharmacological mechanisms. Phytochemical analysis of HEAv used LC-MS, LC-MS/MS, and LC-ESI-IT-MSn. Gastroprotective activity of HEAv (3, 10, or 30 mg/kg) and sabinene (3 mg/kg) was assessed in ethanol- and piroxicam-induced ulcers, beyond pyloric ligation. Healing and recurrence were assessed via acetic acid-induced and IL-1β-triggered ulcers, the latter monitored by ultrasonography. Oxidative stress, inflammatory markers, histology, network pharmacology, and molecular docking/dynamics were evaluated, along with acute toxicity in mice. Chemical analysis identified 36 compounds in HEAv, predominantly phenolics and flavonoids. HEAv and sabinene showed gastroprotective effects, corroborated by mucosal protection and modulation of oxidative stress and inflammatory parameters. In addition, HEAv increased gastric pH, compared to omeprazole. Moreover, HEAv and sabinene reduced ulceration in both the healing and recurrence models, accompanied by increased GSH and CAT activity, and reduced LPO, MPO, and pro-inflammatory cytokines (IL-6 and IL-17A). No acute toxicity was observed. Network pharmacology identified inflammatory signaling as a key target of HEAv constituents, and docking and dynamic molecular assays confirmed favorable, stable interactions between phenolic compounds and sabinene with H+/K+-ATPase and IKKβ, supported by favorable MM-PBSA/MM-GBSA binding energies. HEAv and sabinene exert gastroprotective and healing effects by modulating acid secretion, oxidative stress, and inflammatory cytokines, as suggested by in silico analyses. Nonetheless, further studies are warranted to validate the predicted molecular targets and to elucidate additional pharmacological pathways.

PMID 42869396
Read full article →
PubMedJournal of Ayurveda and integrative medicine2026-10-11

Exploring the potential benefits of Shirodhara as an add-on therapy for alleviating post-COVID anxiety and depression: A case study.

Shamkuwar Manoj M, Pv Anandaraman A, Kataria Dinesh D, Bhatted Santosh S et al.

In this case study, we present a 31-year-old female, a homemaker, who developed persistent symptoms of anxiousness, fatigue, weakness, irritation, anger issues, and difficulty concentrating for nearly 12 months following recovery from COVID-19. She was diagnosed by a consulting psychiatrist with post-COVID anxiety with depression, and had been on anxiolytic and antidepressant medications for the past ten months. She underwent Shirodhara (dripping of medicated oil on the forehead) using Balashwagandhadi taila for 14 days as an add-on therapy, while continuing her conventional medications. Assessments at baseline, 8th day, 15th day, and 30th day showed progressive improvements: Hamilton Anxiety Rating Scale (HAM-A) scores reduced from 42 to 10, Hamilton Depression Rating Scale (HDRS) from 23 to 6, Patient Health Questionnaire-9 (PHQ-9) from 24 to 1, and Flanagan Quality of Life Scale (QOLS) improved from 59 to 79 by the 30th day. Serum cortisol was 3.09 μg/dL at baseline, below the normal range, and returned to the normal physiological range (11.76 μg/dL) on the 15th day, reflecting improved stress adaptation. C-Reactive Protein remained stable, while Systemic Immune-Inflammation Index showed a transient, non-pathological rise within normal limits. Also, based on the evaluation and recommendation of the psychiatrist, the dosage of conventional medications was reduced: Propranolol was tapered from 20 mg twice daily to once daily, Clonazepam 0.5 mg at bedtime was shifted to as-needed use, and Omeprazole was discontinued. This case highlights the potential role of Shirodhara as an adjunctive therapy in post-COVID anxiety, along with depression. These findings require validation through larger studies with long-term follow-up.

PMID 42858603
Read full article →
PubMedMikrochimica acta2026-10-09

Inkjet-printed paper-based electrochemical cell with a molecularly imprinted polymer for omeprazole detection in water.

Seguro Isabel I, Poza-Nogueiras Verónica V, González-Veloso Iván I, Cordeiro M Natália D S MNDS et al.

A simple and low-cost inkjet-printed paper-based electrochemical cell incorporating a molecularly imprinted polymer (MIP) was developed for the selective detection of omeprazole (OPZ). Waterproof paper was used as the substrate for the fabrication of the electrochemical cell by inkjet printing of silver and gold conductive inks, followed by modification of the working electrode with carbon ink. The resulting cell showed good electrochemical performance, with an enhanced voltammetric response towards OPZ compared with conventional screen-printed electrodes. Printing parameters and electrode composition were optimised, and the morphology was confirmed by scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDS). The functional monomer was rationally selected through computational studies based on BSSE-corrected binding energies, avoiding a trial-and-error approach. The recognition element was then obtained by electropolymerisation of p-aminobenzene sulfonic acid in the presence of OPZ, forming an imprinted polymer directly on the electrode surface. Under optimised conditions, the sensor exhibited a linear response between 0.50 and 50 µM, with limits of detection and quantification of 0.14 µM and 0.47 µM, respectively, and good selectivity against structurally related compounds. The cell was successfully applied to spiked river and well water samples, without any pre-treatment, achieving recoveries ranging from 89% to 112%. Combining simple fabrication, low cost and portability, this inkjet-printed paper-based MIP sensor shows strong potential for the on-site monitoring of pharmaceutical contaminants.

PMID 42853342
Read full article →
PubMedDigestive diseases (Basel, Switzerland)2026-10-07

IS PYLERA® STILL EFFECTIVE AND SAFE IN PATIENTS INFECTED BY HELICOBACTER PYLORI? A SIX-YEARS, MULTICENTRE, REAL LIFE STUDY.

Di Mario Francesco F, Franceschi Marilisa M, Elisei Walter W, Crafa Pellegrino P et al.

More than ten years after its introduction into clinical practice, we aimed to assess the current real-life effectiveness and safety of bismuth-containing quadruple therapy in patients infected with H. pylori. Consecutive dyspeptic H. pylori-positive patients were enrolled, both naïve for treatment and already unsuccessfully treated. Patients received Pylera® 3 capsules four times daily plus omeprazole 20 mg or esomeprazole 40 mg bid for 10 days. Eradication was confirmed using a urea-breath test (at least 30 days after the end of treatment). We assessed effectiveness and safety in these patients. One thousand and eighteen consecutive patients were included in the study, 648 (63.7%) treated as first-line and 370 (36.3%) treated after failure of at least one previous eradication course. The vast majority of patients were fully compliant, except 18 (1.8%) subjects, who discontinued treatment due to severe adverse events. H. pylori eradication was achieved in 959/1,000 (95.9%, CI 94.7-97.1%) patients, higher in naïve than in previously treated patients (97.3%, CI 96.1-98.6%, vs 93.3%, CI 90.8-95.9%; p=0.002). Overall, the eradication rate remains significantly high during the observational period. In particular, it was 100% in 2020, 97.8% (CI 95.7-99.9%) in 2021, 100% in 2022, 98.8% (CI 97.3-100%) in 2023, 89.1% (CI 84.6-93.6%) in 2024, and 97.8% (CI 95.5-100%) in 2025: the failures, although minimal, were more present in 2024 (P<0.001). Finally, the eradication rate remained constant from 2020 to 2025. Pylera® remains an effective and safe therapeutic option for curing H. pylori infection in both naïve and previously treated patients.

PMID 42842495
Read full article →

+9724 more articles available with a free account

Sign up free to view all articles →

Ask about omeprazole